BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 34714275)

  • 1. The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer.
    Kimura H; Klein AP; Hruban RH; Roberts NJ
    Pancreas; 2021 Sep; 50(8):1123-1130. PubMed ID: 34714275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance.
    Kimura H; Paranal RM; Nanda N; Wood LD; Eshleman JR; Hruban RH; Goggins MG; Klein AP; ; Roberts NJ
    Elife; 2022 Jan; 11():. PubMed ID: 35001868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations.
    Lal G; Liu L; Hogg D; Lassam NJ; Redston MS; Gallinger S
    Genes Chromosomes Cancer; 2000 Apr; 27(4):358-61. PubMed ID: 10719365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.
    McWilliams RR; Wieben ED; Rabe KG; Pedersen KS; Wu Y; Sicotte H; Petersen GM
    Eur J Hum Genet; 2011 Apr; 19(4):472-8. PubMed ID: 21150883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.
    Horn IP; Marks DL; Koenig AN; Hogenson TL; Almada LL; Goldstein LE; Romecin Duran PA; Vera R; Vrabel AM; Cui G; Rabe KG; Bamlet WR; Mer G; Sicotte H; Zhang C; Li H; Petersen GM; Fernandez-Zapico ME
    J Biol Chem; 2021; 296():100634. PubMed ID: 33823155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene-Level Associations in Patients With and Without Pathogenic Germline Variants in
    Astiazaran-Symonds E; Graham C; Kim J; Tucker MA; Ingvar C; Helgadottir H; Pastorino L; van Doorn R; Sampson JN; Zhu B; Bruno W; Queirolo P; Fornarini G; Sciallero S; Carter B; Hicks B; Hutchinson A; Jones K; Stewart DR; Chanock SJ; Freedman ND; Landi MT; Höiom V; Puig S; Gruis N; Yang XR; Ghiorzo P; Goldstein AM
    JCO Precis Oncol; 2022 Nov; 6():e2200145. PubMed ID: 36409970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk.
    Campa D; Pastore M; Gentiluomo M; Talar-Wojnarowska R; Kupcinskas J; Malecka-Panas E; Neoptolemos JP; Niesen W; Vodicka P; Delle Fave G; Bueno-de-Mesquita HB; Gazouli M; Pacetti P; Di Leo M; Ito H; Klüter H; Soucek P; Corbo V; Yamao K; Hosono S; Kaaks R; Vashist Y; Gioffreda D; Strobel O; Shimizu Y; Dijk F; Andriulli A; Ivanauskas A; Bugert P; Tavano F; Vodickova L; Zambon CF; Lovecek M; Landi S; Key TJ; Boggi U; Pezzilli R; Jamroziak K; Mohelnikova-Duchonova B; Mambrini A; Bambi F; Busch O; Pazienza V; Valente R; Theodoropoulos GE; Hackert T; Capurso G; Cavestro GM; Pasquali C; Basso D; Sperti C; Matsuo K; Büchler M; Khaw KT; Izbicki J; Costello E; Katzke V; Michalski C; Stepien A; Rizzato C; Canzian F
    Oncotarget; 2016 Aug; 7(35):57011-57020. PubMed ID: 27486979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study.
    Furniss CS; Yurgelun MB; Ukaegbu C; Constantinou PE; Lafferty CC; Talcove-Berko ER; Schwartz AN; Stopfer JE; Underhill-Blazey M; Kenner B; Nelson SH; Okumura S; Law S; Zhou AY; Coffin TB; Rodriguez NJ; Uno H; Ocean AJ; McAllister F; Lowy AM; Lippman SM; Klein AP; Madlensky L; Petersen GM; Garber JE; Goggins MG; Maitra A; Syngal S
    Cancer Prev Res (Phila); 2021 Nov; 14(11):1021-1032. PubMed ID: 34625409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.
    Vasen H; Ibrahim I; Ponce CG; Slater EP; Matthäi E; Carrato A; Earl J; Robbers K; van Mil AM; Potjer T; Bonsing BA; de Vos Tot Nederveen Cappel WH; Bergman W; Wasser M; Morreau H; Klöppel G; Schicker C; Steinkamp M; Figiel J; Esposito I; Mocci E; Vazquez-Sequeiros E; Sanjuanbenito A; Muñoz-Beltran M; Montans J; Langer P; Fendrich V; Bartsch DK
    J Clin Oncol; 2016 Jun; 34(17):2010-9. PubMed ID: 27114589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic
    Overbeek KA; Rodríguez-Girondo MD; Wagner A; van der Stoep N; van den Akker PC; Oosterwijk JC; van Os TA; van der Kolk LE; Vasen HFA; Hes FJ; Cahen DL; Bruno MJ; Potjer TP
    J Med Genet; 2021 Apr; 58(4):264-269. PubMed ID: 32482799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline sequence analysis of RABL3 in a large series of pancreatic ductal adenocarcinoma patients reveals no evidence of deleterious variants.
    Roberts NJ; Grant RC; Gallinger S; Klein AP;
    Genes Chromosomes Cancer; 2021 Aug; 60(8):559-564. PubMed ID: 33724601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDKN2A is the main susceptibility gene in Italian pancreatic cancer families.
    Ghiorzo P; Fornarini G; Sciallero S; Battistuzzi L; Belli F; Bernard L; Bonelli L; Borgonovo G; Bruno W; De Cian F; Decensi A; Filauro M; Faravelli F; Gozza A; Gargiulo S; Mariette F; Nasti S; Pastorino L; Queirolo P; Savarino V; Varesco L; Scarrà GB;
    J Med Genet; 2012 Mar; 49(3):164-70. PubMed ID: 22368299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations.
    Yang XR; Rotunno M; Xiao Y; Ingvar C; Helgadottir H; Pastorino L; van Doorn R; Bennett H; Graham C; Sampson JN; Malasky M; Vogt A; Zhu B; Bianchi-Scarra G; Bruno W; Queirolo P; Fornarini G; Hansson J; Tuominen R; Burdett L; Hicks B; Hutchinson A; Jones K; Yeager M; Chanock SJ; Landi MT; Höiom V; Olsson H; Gruis N; Ghiorzo P; Tucker MA; Goldstein AM
    Hum Genet; 2016 Nov; 135(11):1241-1249. PubMed ID: 27449771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic Cancer Surveillance in Carriers of a Germline
    Klatte DCF; Boekestijn B; Wasser MNJM; Feshtali Shahbazi S; Ibrahim IS; Mieog JSD; Luelmo SAC; Morreau H; Potjer TP; Inderson A; Boonstra JJ; Dekker FW; Vasen HFA; van Hooft JE; Bonsing BA; van Leerdam ME
    J Clin Oncol; 2022 Oct; 40(28):3267-3277. PubMed ID: 35658523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Growth Rate of Pancreatic Ductal Adenocarcinoma in
    Ibrahim IS; Wasser MN; Wu Y; Inderson A; de Vos Tot Nederveen Cappel WH; Morreau H; Hes FJ; Veenendaal RA; Putter H; Feshtali S; van Mil AM; Gruis NA; Tollenaar RA; Bergman W; Bonsing BA; Vasen HFA
    Cancer Prev Res (Phila); 2018 Sep; 11(9):551-556. PubMed ID: 29991580
    [No Abstract]   [Full Text] [Related]  

  • 16. Surgical outcomes after pancreatic surgery in patients with a germline CDKN2A/p16 pathogenic variant under surveillance.
    Onnekink AM; Michiels N; Klatte DCF; Oldenburg L; Mieog JSD; Vahrmeijer AL; van Hooft JE; van Leerdam ME; Bonsing BA
    Br J Surg; 2024 Jan; 111(1):. PubMed ID: 38156443
    [No Abstract]   [Full Text] [Related]  

  • 17. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma.
    Shindo K; Yu J; Suenaga M; Fesharakizadeh S; Cho C; Macgregor-Das A; Siddiqui A; Witmer PD; Tamura K; Song TJ; Navarro Almario JA; Brant A; Borges M; Ford M; Barkley T; He J; Weiss MJ; Wolfgang CL; Roberts NJ; Hruban RH; Klein AP; Goggins M
    J Clin Oncol; 2017 Oct; 35(30):3382-3390. PubMed ID: 28767289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic carcinoma surveillance in patients with familial melanoma.
    Parker JF; Florell SR; Alexander A; DiSario JA; Shami PJ; Leachman SA
    Arch Dermatol; 2003 Aug; 139(8):1019-25. PubMed ID: 12925390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3'UTR-CDKN2A and CDK4 Germline Variants Are Associated With Susceptibility to Cutaneous Melanoma.
    Tovar-Parra D; Gil-Quiñones SR; Nova J; Gutiérrez-Castañeda LD
    In Vivo; 2021; 35(3):1529-1536. PubMed ID: 33910831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel CDKN2A in-frame deletion associated with pancreatic cancer-melanoma syndrome.
    Bottillo I; Valiante M; Menale L; Paiardini A; Papi L; Janson G; Sestini R; Iorio A; De Simone P; Frascione P; Grammatico P
    Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.